Document ID: chunk:federal_register_of_legislation:F2024L00743:reg:9:p1
Version: federal_register_of_legislation:F2024L00743
Segment Type: reg
Provision Reference: reg 9 (pt 1/8)
Character Range: 4129–7768

9               Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting cerebrovascular accident (stroke) or death from cerebrovascular accident (stroke) with the circumstances of a person's relevant service:
(1)          having hypertension within the 10 years before clinical onset;
(2)          having a hypertensive emergency or crisis at the time of clinical onset;
Note: hypertensive emergency or crisis is defined in the Schedule 1 - Dictionary.
(3)          inability to undertake any physical activity greater than three METs for at least 5 years within the 20 years before clinical onset;
Note: MET is defined in the Schedule 1 - Dictionary.
(4)          consuming alcohol in an amount of at least 250 grams per week, for at least the 1 year before clinical onset;
(5)          for brain ischaemia only, binge drinking 300 grams of alcohol within the 7 days before clinical onset;
(6)          for intra-cerebral haemorrhage only, binge drinking:
(a)          90 grams of alcohol within the 24 hours; or
(b)          180 grams of alcohol within the 7 days;
before clinical onset;
(7)          having one of the following brain infections within the 4 weeks before clinical onset:
(a)          cerebral abscess;
(b)          cerebral helminthic infection (cysticercosis, schistosomiasis, sparganosis);
(c)          cerebral malaria;
(d)          encephalitis;
(e)          infectious vasculitis;
(f)           intracerebral fungal infection (aspergillosis, coccidioidomycosis, Cryptococcus, histoplasmosis or mucormycosis);
(g)          meningitis (syphilis, tuberculosis, fungal, bacterial, viral);
(h)          neurosyphilis; or
(i)            tuberculosis;
(8)          having a Varicella-zoster virus infection, involving the brain, within the 1 year before clinical onset;
(9)          having infection with human immunodeficiency virus before clinical onset;
(10)      having one of the following systemic inflammatory disorders causing cerebral vasculitis at the time of clinical onset:
(a)          ankylosing spondylitis;
(b)          dermatomyositis;
(c)          inclusion body myositis;
(d)          polymyositis;
(e)          psoriatic arthritis;
(f)           rheumatoid arthritis;
(g)          systemic sclerosis (scleroderma);
(h)          Sjögren syndrome; or
(i)            systemic lupus erythematosus.
(11)      having gout at the time of clinical onset;
(12)      having one of the following vasculitides at the time of  clinical onset:
(a)          antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis;
(b)          Behcet disease;
(c)          eosinophilic granulomatosis with polyangiitis (Churg Straus syndrome);
(d)          giant cell (temporal) arteritis;
(e)          granulomatosis with polyangiitis (Wegener granulomatosis);
(f)           Immunoglobulin A vasculitis (Henoch-Schönlein purpura);
(g)          microscopic polyangiitis;
(h)          neurosarcoidosis;
(i)            mucocutaneous lymph node syndrome (Kawasaki disease);
(j)            primary angiitis of the central nervous system;
(k)          polyarteritis nodosa;
(l)            Takayasu arteritis; or
(m)        thromboangiitis obliterans (Buerger disease);
(13)      having one of the following vessel disorders at the time of clinical onset:
(a)          atheroma of the penetrating arteries that arise from the vertebral artery, the basilar artery, the middle cerebral artery stem, and the arteries of the circle of Willis;
(b)          cerebral amyloid angiopathy;
(c)          cerebral arteriolosclerosis;